$SAGE News
Last published 1y ago
- 1y agoSAGESUPNSupernus Pharmaceuticals Completes Acquisition of Sage TherapeuticsGlobeNewswireROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics,
- 1y agoSAGESage Therapeutics Announces Second Quarter 2025 Financial ResultsBusiness WireAchieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously
- 1y agoSAGESUPNSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender OfferGlobeNewswireROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period
- 1y agoBIIBSAGEZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionGlobeNewswireCAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion
- 1y agoATAICMPSCYBNMNMD+1Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032GlobeNewswirePALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years
- 1y agoPHATSAGEPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate SecretaryGlobeNewswireFLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)
- 1y agoSAGESUPNSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioGlobeNewswireProposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative
- 1y agoSAGESage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business UpdatesBusiness WireAchieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained
- 1y agoSAGEKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) ...
- 1y agoSAGESage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025Business WireSage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The
- 1y agoFLNCKYTXMRCYSAGENotice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 17, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ:FLNC): Grabar Law Office is investigating claims on behalf of Fluence Energy, Inc. (NASDAQ:FLNC) shareholders. The investigation concerns
- 1y agoFLNCKYTXMRCYSAGELong-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ:FLNC): Grabar Law Office is investigating claims on behalf of Fluence Energy, Inc. (NASDAQ:FLNC) shareholders. The investigation concerns
- 1y agoSAGESage Therapeutics Announces R&D Leadership TransitionBusiness WireSage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage
- 1y agoSAGESage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business UpdatesBusiness WireStrong first full year of launch with sustained growth in shipments to women with postpartum depression; Nearly 2,500 shipments in fourth quarter of 2024 (21% increase from third quarter) $11.4 million in
- 1y agoSAGESage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025Business WireSage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent
- 1y agoBIIBSAGESage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition ProposalBusiness WireCompany Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care
- 1y agoSAGESage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare ConferenceBusiness WireIncreased investment in ZURZUVAE to help accelerate market growth in postpartum depression with the goal of topline revenue growth in 2025 R&D and G&A expenses expected to decrease substantially in
- 1y agoSAGESage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025Business WireSage Therapeutics, Inc. (NASDAQ:SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live
- 1y agoSAGESage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceBusiness WireSage Therapeutics, Inc. (NASDAQ:SAGE), today announced that the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:00 a.m. ET in New
- 1y agoSAGESage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's DiseaseBusiness WireThe Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan further development of
- 2y agoSAGESage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAGESage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business UpdatesBusiness WireAchieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen
- 2y agoSAGEINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sage Therapeutics, Inc. ("Sage" or the...
- 2y agoSAGESage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development PortfolioBusiness WirePlanned workforce reduction of approximately 33% of employees expected to extend the company's cash runway Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced a strategic reorganization of its business operations to
- 2y agoSAGEShareholders of Sage Therapeutics, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - SAGEPR NewswireThe Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE...
- 2y agoSAGESage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024Business WireSage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business
- 2y agoSAGESage Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – SAGEGlobeNewswireNEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ:SAGE). Shareholders who purchased shares of SAGE during the class period
- 2y agoBIIBSAGETalkiatry Expands Postpartum Depression Care Services to Close Gaps in Maternal Mental HealthcarePR NewswireTalkiatry, a leading provider of high-quality, in-network psychiatric care, today announced a new pathway for postpartum mental health support that...
- 2y agoSAGESage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's DiseaseBusiness Wire- In the Phase 2 LIGHTWAVE Study, dalzanemdor (SAGE-718) did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint -
- 2y agoSAGESage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 ProgramBusiness WireSage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Biogen has
- 2y agoSAGEDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoSAGEThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGEPR NewswireThe Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE...
- 2y agoSAGEThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGEPR NewswireThe Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE...
- 2y agoSAGESage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAGESage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressBusiness WireAchieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than
- 2y agoBIIBSAGESage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential TremorBusiness Wire- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were
- 2y agoSAGESage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024Business WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET
- 2y agoSAGESage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington's DiseaseBusiness WireThe SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and
- 2y agoSAGESage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs
- 2y agoSAGESage Therapeutics to Participate in Upcoming May Investor ConferencesBusiness WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor
- 2y agoSAGESage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAGESage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressBusiness WireAchieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than
- 2y agoSAGESage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's DiseaseBusiness Wire- In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients with mild cognitive impairment in Parkinson's disease -
- 2y agoSAGESage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024Business WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET
- 2y agoSAGESage Therapeutics to Present at Upcoming March Investor ConferencesBusiness WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences
- 2y agoSAGESAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSAGESage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business ProgressBusiness WireZURZUVAE™ (zuranolone), the first-and-only oral treatment indicated for adults with postpartum depression (PPD), became commercially available mid-December; Sage achieved $0.8 million in collaboration revenue as
- 2y agoBIIBESALYSAGEBiogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapiesCNBCThe results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
- 2y agoSAGESage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024Business WireSage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00
- 2y agoSAGESage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare ConferenceBusiness WireExcitement over December 2023 launch of ZURZUVAE™ (zuranolone), the first and only oral treatment indicated for adults with postpartum depression (PPD) Continued progress on clinical pipeline, with topline data